Title:
EGFR INHIBITOR AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/216871
Kind Code:
A1
Abstract:
A compound having a structure of formula (I), (IA), (II) or (IIA), or a pharmaceutically acceptable salt thereof, and an application of the compound or salt thereof in inhibiting an EGFR comprising a mutant EGFR, comprising treating cancers associated with, for example, abnormal EGFR activity.
Inventors:
CHEN JINSHAN MICHAEL (CN)
CHOPRA RAJIV (CN)
GU JIAMIN (CN)
CHOPRA RAJIV (CN)
GU JIAMIN (CN)
Application Number:
PCT/CN2023/090563
Publication Date:
November 16, 2023
Filing Date:
April 25, 2023
Export Citation:
Assignee:
ALLIANTHERA SUZHOU BIOPHARMACEUTICAL CO LTD (CN)
International Classes:
C07D498/22; A61K31/439; A61P35/02; C07D487/22
Domestic Patent References:
| WO2022204544A1 | 2022-09-29 |
Foreign References:
| CN114057771A | 2022-02-18 | |||
| CN114007698A | 2022-02-01 | |||
| CN114163454A | 2022-03-11 |
Other References:
ENGELHARDT, H. ET AL.: "Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 62, 5 November 2019 (2019-11-05), XP055821569, DOI: 10.1021/acs.jmedchem.9b01169
Attorney, Agent or Firm:
CHINA PAT INTELLECTUAL PROPERTY OFFICE (CN)
Download PDF: